
Tesla deepens CATL ties to reshape ESS rivalry in US
Tesla dropped a bombshell by recently sharing a video clip on X showing drone footage of its lithium iron phosphate (LFP) battery cell manufacturing facility for energy storage systems in the US state of Nevada. The post read, 'Nearing completion' of its first-ever LFP cell production site in North America.
While the electric vehicle giant is known for pioneering cylindrical lithium-ion battery cells for cars, Tesla's venture into LFP cells sends a warning signal to Korean battery manufacturers, as it potentially enables the Chinese battery giant CATL to indirectly enter the US market despite trade barriers against China.
Rare US-China tie-up
According to Bloomberg, Tesla — already using CATL's LFP cells in its 'Megapack' product for utility- and grid-level ESS, manufactured outside the US — will utilize equipment and battery design from CATL at its Nevada facility.
'Tesla's completion of its LFP cell factory will effectively be equivalent to an indirect entry of CATL into the US market,' said Park Cheol-wan, a car engineering professor at Seojeong University.
'Tesla sources LFP batteries for energy storage and electric vehicles from CATL and BYD, with BYD's long cells serving Europe and CATL's prismatic cells targeting Asia and North America,' Park added. 'With increased US sanctions on China under the Biden administration, Tesla planned to start local production at its Nevada factory. This strategy has shown unexpected foresight, especially in light of the tariffs imposed during Donald Trump's presidency.'
Park noted that CATL's entry through Tesla differs from its 'de facto failed attempt' to build a joint battery manufacturing plant with Ford Motor Company, which involved licensing its battery technology. With Tesla having full control over the Nevada factory, CATL can still benefit financially from supplying equipment, thereby deepening its reach into an otherwise 'impenetrable' US market.
Fresh threat to LG?
Tesla and CATL's LFP battery production intensifies pressure on LG Energy Solution, which last month became the first among US-based players to begin mass production of LFP cells for ESS at its Michigan plant.
An LG Energy Solution official noted that the company is now supplying long-cell-based LFP battery pack products to major US energy solution providers, including Terra-Gen and Delta Electronics. The combined annual supply volume to these two firms is projected to reach 12 gigawatt-hours, valued at approximately 3 trillion won ($2.2 billion).
In 2022, LG Energy Solution also entered the ESS system integration sector, moving beyond battery supply to the construction and operation of large-scale ESS in North America.
'Although this move strengthens their market position, we'll need to wait and see whether they can maintain price competitiveness against Tesla, which is collaborating with the cost-efficient CATL,' Park said.
While Tesla does not disclose its exact market share in the US ESS sector, it is known to be a dominant player in residential ESS and a key supplier for utility-scale storage. In 2024, the combined energy storage capacity of Tesla's Megapack and Powerwall products soared 114 percent year-on-year to 31.4 gigawatt-hours. The company projects at least 50 percent growth in this segment for 2025.
No clear leader
Industry watchers expect the LFP battery rivalry between LG Energy Solution and Tesla — backed by CATL — to expand into the US electric vehicle market.
'While Tesla has so far only revealed plans for ESS production at its Nevada plant, it seems only a matter of time before it begins manufacturing LFP cells for EVs as well, given that these products use the same battery design,' said a researcher at a major Korean battery company.
Park also noted that Tesla's local production of LFP cells is likely to spur LG Energy Solution — which is set to begin large-scale LFP battery supplies to Renault Group from its plant in Poland — to explore new partnerships with legacy US automakers such as Ford Motor Company and General Motors.
In the first quarter of this year, GM's brands — Chevrolet, Cadillac and GMC — ranked second in US EV sales with 31,886 units, following Tesla's 128,100 units, according to data from Cox Automotive. Ford came in third with 22,500 units sold.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 hours ago
- Korea Herald
SolidVue and Lumotive Collaborate to Advance Next-Generation LiDAR Systems
SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- SolidVue, a leader in SPAD sensor IC technology, announced a strategic collaboration with Lumotive, a US-based pioneer in programmable optical semiconductors, to develop next-generation LiDAR systems. The partnership brings together industry-leading technologies from both companies, aimed at transforming the future of 3D sensing. This collaboration will focus on developing a reference design that integrates SolidVue's high-performance dTOF SPAD array receiver with Lumotive's breakthrough Light Control Metasurface (LCM™) beamforming chip. The resulting system is expected to deliver high performance in resolution, precision, and efficiency for LiDAR module and system developers across a wide range of industries. The partnership underscores a shared vision for enabling high-performance, compact, and cost-effective LiDAR solutions that accelerate adoption in key markets such as autonomous vehicles, industrial automation, and smart devices. "By combining our advanced SPAD receiver technology with Lumotive's cutting-edge beam steering chips, we aim to push the boundaries of what LiDAR systems can achieve," said Jung-Hoon Chun, Co-CEO of SolidVue. "This collaboration is an important step toward realizing our mission of delivering high-resolution, reliable LiDAR sensor ICs to the global market." Dr. Sam Heidari, CEO of Lumotive, added, "By combining SolidVue's sensor innovation with our LCM technology, we're redefining what's possible in LiDAR performance and paving the way for next-generation applications. The collaboration between our two companies highlights the synergy of our visions and technologies, and we are excited about the potential impact across multiple industries." With complementary strengths and aligned goals, SolidVue and Lumotive are committed to enabling a new class of LiDAR systems that offer superior performance, scalability, and design flexibility for next-generation applications. About SolidVue SolidVue, headquartered in South Korea, specializes in the development of advanced LiDAR sensor ICs. The company has pioneered the integration of CMOS SPAD (Single Photon Avalanche Diode) technology, enabling high-resolution 3D imaging with enhanced precision and depth accuracy. Its LiDAR sensor solutions are designed for applications in autonomous driving, AR/VR, and smart devices, offering compact form factors and cost efficiency.

Korea Herald
5 hours ago
- Korea Herald
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea. The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs. "In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs," said Yohan Kim, Senior Managing Director at DSC Investment, who led this investment round and has also been appointed to the board of directors. Jiwoong Chun, Managing Director at Woori Venture Partners and an active board member and investor since the company's inception, added, "Illimis is a prime example of a smart Korean biotech unlocking global markets with proprietary innovation and capital efficiency." Illimis has recently been selected for the '2025 Global Joint Research to Defeat Dementia' led by the Ministry of Health and Welfare and the Korean Dementia Research Center, securing KRW 2.2 million ($1.6 million) in funding over three years, further validating its technological capabilities. This initiative aims to develop Alzheimer's therapeutics through global joint research leveraging the GAIA platform, positioning Illimis at the center of international collaboration. Furthermore, in October 2024, Illimis partnered with Eli Lilly and Company (Lilly)'s Catalyze360-ExploR&D, a core pillar of external innovation at Lilly dedicated to deploying world-leading research and development capabilities and scientific know-how to accelerate partner science. Under this research collaboration, Illimis and Lilly have been cooperating to advance the platform construct for applications in neurodegenerative diseases. Illimis has also strengthened its global pharma collaborations by winning the 2023 BMS Innovation Square Challenge and joining Johnson & Johnson's global incubator network as a member company of JLABS Singapore in 2024. To further enhance its drug development competitiveness, Illimis Therapeutics operates a Scientific Advisory Board (SAB). The SAB includes Dr. Greg Lemke, Emeritus Professor at the Salk Institute and a world-renowned expert in TAM Biology, and Dr. Morgan Sheng, a leading neuroscientist at the Broad Institute who previously served as Vice President of Neuroscience at Genentech. These experts provide strategic guidance across the entire R&D lifecycle, including pipeline development, candidate discovery, clinical trial design, etc., and play a pivotal role in strengthening Illimis Therapeutics' global partnerships. "This investment, government grants, and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology," said Sanghoon Park, CEO of Illimis Therapeutics. "We will continue to focus on innovative new drug development centered around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D collaboration models." About Illimis Therapeutics Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses. The company's lead pipeline, ILM01 for the treatment of Alzheimer's Disease, is entering into the preclinical stage in the second half of 2025 and expecting to submit an IND by the end of 2027. For more information, visit


Korea Herald
6 hours ago
- Korea Herald
Arrest warrants sought for construction firm officials in case allegedly involving ex-first lady
The special counsel team investigating allegations involving former first lady Kim Keon Hee filed for warrants Monday to arrest four construction company officials over a stock manipulation case allegedly linked to her. The investigation team, led by special counsel Min Joong-ki, said it filed the warrants against Lee Il-jun and Cho Sung-wok, current and former chairman of Sambu Construction Co., respectively, along with a former vice chairman and a former CEO, on charges of violating the Capital Markets Act. It marks the first time arrest warrants have been sought by the special counsel team since it launched its investigation into allegations involving Kim earlier this month. The four executives are accused of allegedly duping investors into buying the firm's shares in 2023 on false information that it would take part in reconstruction projects in war-torn Ukraine, then selling off their shares at inflated prices to pocket massive illegal profits. The former first lady is alleged to have played a role in the scheme. Also on Monday, the special counsel team summoned the founder of Kakao Corp. and executives of several other companies for questioning over an investment scandal linked to one of Kim's aides. Kakao founder Kim Beom-su; vice chairman of HS Hyosung Corp. Jo Hyeong-sang; former president of the Korea Securities Finance Corp. Yoon Chang-ho; and former Daou Kiwoom Group Chairman Kim Ik-rae were told to appear for questioning at 10 a.m. Thursday. The scandal centers on allegations that a man surnamed Kim, who served as a "butler" for the former first lady's family, had reportedly received 18 billion won (US$13 million) in illegal investments from several companies, including Kakao Mobility Corp., for his rental car company, IMS, in 2023. The special counsel suspects that the funds invested in IMS may have been funneled to the former first lady in the form of slush funds. The executives were summoned as witnesses in the case, though their status could change to suspects depending on the outcome of the probe, officials said. "We will begin questionings of top decision makers of the companies (involved) ... this week to swiftly find the truth behind the so-called 'butler gate' and prevent the destroying of evidence," assistant special counsel Oh Jung-hee said in a regular press briefing.